Table 2.
Recommendations for treatment and follow-up in different clinical scenarios, according to Asian Pacific Association for the Study of the Liver, American Association for the Study of Liver Disease and European Association for the Study of the Liver guidelines
|
Recommendations in different clinical scenarios |
|||||
| HBsAg (+) HBV DNA ≥ 2000 U/mL | HBsAg (+) HBV DNA < 2000 U/mL | HBsAg (-) antiHBc (+) | HBsAg (-) antiHBc (-) antiHBs (-) | HBV-HCC TACE | |
| Action | Treat | Treat | Close mon/treat if HBV DNA (+) or rituximab/stem cell transplant1 | Vaccination | Treat3 |
| Onset | Before IS | Before IS | Before IS | - | Before IS |
| Duration | 6-12 mo (except CI) | 6-12 mo (except CI) | 6-12 mo | - | - |
| Drug | Short IS: LAM (LdT) preferred ETV/TDF | Short IS: LAM (LdT) (ETV/TDF) | Short IS: LAM (LdT) (ETV/TDF) | - | LAM (ETV/TDF) |
| Follow-up | - | - | Every 1-3 mo/treat if HBV DNA (+)2 | - | - |
In HBsAg-positive patients, duration could be determined by CI as in immunocompetent patients. A 12-mo treatment was only endorsed by EASL. Drug selection depends on treatment duration and clinical setting.
In isolated antiHBc-positive patients when treated with biologic agents, close follow-up and treatment, if necessary, is suggested by AASLD/APASL; however, EASL proposes that isolated antiHBc-positive patients, if HBV DNA-positive, antiHBs-negative or undergoing rituximab/stem cell transplantation, should be treated with the same strategy as HBsAg positive patients;
When monitored, treatment should start when HBV DNA becomes positive, before ALT rise (EASL);
Treatment in all HBV-related HCC patients undergoing TACE is suggested by APASL guidelines. CI: Clinical indication; IS: Immunosuppression; HBsAg: Hepatitis B surface antigen; AntiHBc: Hepatitis B core antibody; AntiHBs: Hepatitis B surface antibody; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; LAM: Lamivudine; ETV: Entecavir; TDF: Tenofovir; LdT: Telbivudine (only listed as an option in AASLD guidelines); AASLD: American Association for the Study of Liver Disease; APASL: Asian Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver.